Middleton & Co Inc MA purchased a new position in Perrigo Company (NYSE:PRGO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,950 shares of the company’s stock, valued at approximately $223,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of PRGO. Fox Run Management L.L.C. increased its stake in Perrigo by 17.2% in the first quarter. Fox Run Management L.L.C. now owns 7,500 shares of the company’s stock worth $498,000 after buying an additional 1,100 shares during the last quarter. Bank of Montreal Can increased its position in Perrigo by 10.8% in the first quarter. Bank of Montreal Can now owns 82,020 shares of the company’s stock valued at $5,445,000 after buying an additional 8,012 shares in the last quarter. Chevy Chase Trust Holdings Inc. increased its position in Perrigo by 3.2% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 123,597 shares of the company’s stock valued at $8,205,000 after buying an additional 3,792 shares in the last quarter. Macquarie Group Ltd. increased its position in Perrigo by 1.7% in the fourth quarter. Macquarie Group Ltd. now owns 103,300 shares of the company’s stock valued at $8,597,000 after buying an additional 1,685 shares in the last quarter. Finally, Philadelphia Trust Co. increased its position in Perrigo by 2.4% in the fourth quarter. Philadelphia Trust Co. now owns 94,190 shares of the company’s stock valued at $7,839,000 after buying an additional 2,178 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Shares of Perrigo Company (NYSE:PRGO) traded down 0.49% during midday trading on Wednesday, hitting $72.54. The company’s stock had a trading volume of 206,145 shares. Perrigo Company has a 12-month low of $65.47 and a 12-month high of $99.14. The firm has a 50-day moving average of $73.16 and a 200 day moving average of $73.82. The firm’s market cap is $10.40 billion.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Tuesday, May 30th. The company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.06. Perrigo had a positive return on equity of 11.79% and a negative net margin of 43.81%. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.19 billion. During the same period in the previous year, the firm posted $1.32 earnings per share. The company’s revenue was down 11.4% on a year-over-year basis. On average, equities research analysts predict that Perrigo Company will post $4.28 EPS for the current fiscal year.

WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/07/19/middleton-co-inc-ma-invests-223000-in-perrigo-company-prgo.html.

PRGO has been the topic of several analyst reports. Wells Fargo & Company reissued a “market perform” rating and set a $67.00 target price on shares of Perrigo in a research report on Friday, April 14th. Deutsche Bank AG cut their target price on Perrigo from $87.00 to $86.00 and set a “buy” rating on the stock in a research report on Wednesday, April 19th. B. Riley reissued a “neutral” rating and set a $67.00 target price on shares of Perrigo in a research report on Saturday, April 22nd. Royal Bank Of Canada reissued a “hold” rating and set a $68.00 target price on shares of Perrigo in a research report on Wednesday, May 3rd. Finally, Canaccord Genuity set a $86.00 target price on Perrigo and gave the company a “buy” rating in a research report on Monday, May 22nd. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $86.16.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Institutional Ownership by Quarter for Perrigo (NYSE:PRGO)

Receive News & Stock Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related stocks with our FREE daily email newsletter.